



Vigilancia de la Poliomielitis en las Américas

Cuadro No. 1
Análisis de las muestras de heces de casos
Últimas 52 semanas (2003/15-2004/13)

| Lab. | País | Total* | SIN RESULTADOS | | | % Asla- miento | AISLAMIENTO DE ENTEROVIRUS | | | | |
|-------|------|--------|-------------------|-------------|-------------|-------------------|----------------------------|----------------------|------------|---------|---|
| | | | Aún no en lab. | <28 Días | >28 Días | | Negativo | Otros Enterovirus | Poliovirus | | |
| | | | | | | | | Pendiente | Vacunal | Salvaje | |
| BEL | BRA | 49 | 8 | 0 | 4 | 16,2 | 31 | 2 | 0 | 4 | 0 |
| CAR | DOR | 10 | 0 | 0 | 0 | 20,0 | 8 | 2 | 0 | 0 | 0 |
| | GUY | 9 | 0 | 0 | 0 | 11,1 | 8 | 1 | 0 | 0 | 0 |
| | HAI | 10 | 2 | 0 | 0 | 37,5 | 5 | 2 | 0 | 1 | 0 |
| | HON | 61 | 5 | 7 | 0 | 28,6 | 35 | 12 | 0 | 2 | 0 |
| | JAM | 17 | 0 | 0 | 0 | 5,9 | 16 | 1 | 0 | 0 | 0 |
| | SUR | 7 | 1 | 0 | 0 | 0,0 | 6 | 0 | 0 | 0 | 0 |
| | TRT | 4 | 0 | 0 | 0 | 25,0 | 3 | 1 | 0 | 0 | 0 |
| FIO | BRA | 400 | 117 | 1 | 14 | 16,4 | 224 | 35 | 0 | 9 | 0 |
| | PER | 101 | 8 | 4 | 1 | 11,4 | 78 | 9 | 0 | 1 | 0 |
| INC | ELS | 88 | 0 | 0 | 0 | 36,4 | 56 | 32 | 0 | 0 | 0 |
| | GUT | 102 | 0 | 9 | 3 | 18,9 | 73 | 17 | 0 | 0 | 0 |
| | NIC | 29 | 0 | 0 | 0 | 27,6 | 21 | 8 | 0 | 0 | 0 |
| | PAN | 7 | 0 | 0 | 0 | 28,6 | 5 | 2 | 0 | 0 | 0 |
| INCAP | COR | 11 | 0 | 0 | 0 | 27,3 | 8 | 3 | 0 | 0 | 0 |
| INDRE | MEX | 261 | 0 | 0 | 19 | 26,4 | 178 | 64 | 0 | 0 | 0 |
| INH | VEN | 93 | 0 | 7 | 1 | 3,5 | 82 | 3 | 0 | 0 | 0 |
| INS | COL | 157 | 0 | 8 | 2 | 12,9 | 128 | 16 | 0 | 3 | 0 |
| | ECU | 35 | 0 | 0 | 0 | 5,7 | 33 | 2 | 0 | 0 | 0 |
| ISP | CHI | 24 | 0 | 0 | 0 | 8,3 | 22 | 2 | 0 | 0 | 0 |
| MAL | ARG | 112 | 0 | 6 | 1 | 13,3 | 91 | 9 | 0 | 5 | 0 |
| | BOL | 50 | 14 | 0 | 1 | 5,7 | 33 | 2 | 0 | 0 | 0 |
| | CHI | 44 | 0 | 0 | 0 | 9,1 | 40 | 4 | 0 | 0 | 0 |
| | PAR | 28 | 8 | 0 | 0 | 10,0 | 18 | 2 | 0 | 0 | 0 |
| TOTAL | | 1709 | 163 | 42 | 46 | 17,6 | 1202 | 231 | 0 | 25 | 0 |

* Cada muestra se refiere a un individuo

Muestras de casos solamente

Cuadro No. 2
Poliovirus con diferenciación intratípica pendiente
Últimas 52 semanas (2003/15-2004/13)

| LAB | PAIS | POLIOVIRUS | | | | | | | | | | | | TOTAL |
|-------|------|-------------------|----|----|------|-----------------------|----|----|------|-----------------------|----|----|------|-------|
| | | AÚN NO EN EL LAB, | | | | EN LAB < de 4 semanas | | | | EN LAB > de 4 semanas | | | | |
| | | P1 | P2 | P3 | Mez, | P1 | P2 | P3 | Mez, | P1 | P2 | P3 | Mez, | |
| TOTAL | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

Muestras de casos solamente

LA POLIOMIELITIS HA SIDO ERRADICADA DE LAS AMÉRICAS

El último caso con poliovirus salvaje fue detectado
el 5 de septiembre de 1991, en Perú

El boletín de vigilancia de la poliomielitis se encuentra en:
<http://www.paho.org/spanish/ad/fch/im/poliomyelitis.htm>



Vigilancia de Parálisis Flácida Aguda

Vol, 19, No 13

Cuadro No, 1
Casos de parálisis flácida aguda bajo investigación
según semana de notificación

| PAIS | TOTAL | ACUM. | Semana | | | | | | |
|--------------|------------|------------|-----------|-----------|-----------|-----------|-----------|-----------|----------|
| | 2003 | 2004 | 1-4 | 5-8 | 9 | 10 | 11 | 12 | 13 |
| ARG | 0 | 20 | 5 | 5 | 2 | 3 | 2 | 1 | 2 |
| BOL | 1 | 14 | 2 | 4 | 6 | 1 | 1 | 0 | 0 |
| BRA | 42 | 45 | 18 | 23 | 2 | 1 | 1 | 0 | 0 |
| CAN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CAR | 1 | 10 | 5 | 4 | 0 | 1 | 0 | 0 | 0 |
| CHI | 6 | 11 | 2 | 7 | 0 | 1 | 0 | 0 | 1 |
| COL | 2 | 17 | 3 | 5 | 0 | 6 | 1 | 2 | 0 |
| COR | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| CUB | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DOR | 0 | 5 | 0 | 5 | 0 | 0 | 0 | 0 | 0 |
| ECU | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| ELS | 0 | 15 | 6 | 4 | 2 | 3 | 0 | 0 | 0 |
| GUT | 0 | 14 | 1 | 2 | 3 | 5 | 1 | 2 | 0 |
| HAI | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HON | 0 | 12 | 0 | 4 | 4 | 2 | 2 | 0 | 0 |
| MEX | 140 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| NIC | 0 | 6 | 1 | 4 | 1 | 0 | 0 | 0 | 0 |
| PAN | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| PAR | 0 | 8 | 2 | 3 | 0 | 0 | 1 | 2 | 0 |
| PER | 1 | 13 | 0 | 4 | 1 | 0 | 2 | 3 | 3 |
| URU | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| USA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| VEN | 0 | 8 | 0 | 2 | 1 | 4 | 1 | 0 | 0 |
| Total | 197 | 206 | 49 | 78 | 23 | 27 | 12 | 10 | 7 |

Cuadro No,2
Casos de PFA notificados, tasa por 100,000 <15 años,
% de casos investigados dentro 48 horas, % con 1 muestra
Adecuada y % de unidades notificando semanalmente

| PAIS | Total 2003 | | Ultimas 52 semanas (2003/15-2004/13) | | | | |
|---------------|-------------|-------------|--------------------------------------|-------------|-----------------|--------------|-----------------------|
| | CASOS | TASA | CASOS | TASA | % INV, <48 hrs, | %1 Mues-tra+ | % Sitios Notifi-caron |
| ARG | 122 | 1,19 | 124 | 1,21 | 81 | 65 | 82 |
| BOL | 58 | 1,72 | 50 | 1,48 | 98 | 86 | 0 |
| BRA | 632 | 1,22 | 502 | 0,97 | 97 | 75 | 92 |
| CAN | NR | NR | NR | NR | NR | NR | NR |
| CAR | 43 | 1,95 | 41 | 1,86 | 93 | 63 | 100 |
| CHI | 86 | 2,00 | 70 | 1,62 | 79 | 81 | 96 |
| COL | 164 | 1,17 | 179 | 1,28 | 73 | 76 | 87 |
| COR | 18 | 1,48 | 12 | 0,99 | 100 | 92 | 83 |
| CUB | 25 | 0,56 | 15 | 0,34 | 93 | 93 | 97 |
| DOR | 17 | 0,50 | 15 | 0,44 | 100 | 100 | 89 |
| ECU | 44 | 1,02 | 37 | 0,86 | 84 | 92 | 87 |
| ELS | 106 | 4,60 | 104 | 4,51 | 91 | 90 | 85 |
| GUT | 101 | 2,22 | 108 | 2,37 | 92 | 86 | 66 |
| HAI | 13 | 0,41 | 10 | 3,33 | 70 | 60 | 0 |
| HON | 55 | 2,02 | 61 | 2,24 | 93 | 100 | 94 |
| MEX | 386 | 1,18 | 295 | 0,90 | 95 | 81 | 94 |
| NIC | 37 | 1,62 | 35 | 1,54 | 94 | 100 | 100 |
| PAN | 8 | 0,85 | 8 | 0,85 | 100 | 75 | 88 |
| PAR | 26 | 1,17 | 28 | 1,26 | 86 | 89 | 87 |
| PER | 103 | 1,20 | 103 | 1,20 | 95 | 92 | 99 |
| URU | 10 | 1,22 | 8 | 0,98 | 88 | 50 | 41 |
| USA | NR | NR | NR | NR | NR | NR | NR |
| VEN | 101 | 1,32 | 93 | 1,22 | 96 | 89 | 82 |
| Total§ | 2155 | 1,29 | 1898 | 1,16 | 91 | 81 | 92 |

+ Tomado dentro de los primeros 14 días del inicio de parálisis
 § Excluyendo Canadá y EUA
 NR - No reportes

Cuadro No, 3
Casos confirmados de poliomieltis
por semana de inicio

Hasta la semana 13

| PAIS | TOTAL 2003 | Acumulado | |
|--------------|------------|-----------|----------|
| | | 2003 | 2004 |
| ARG | 0 | 0 | 0 |
| BOL | 0 | 0 | 0 |
| BRA | 0 | 0 | 0 |
| CAN | 0 | 0 | 0 |
| CAR | 0 | 0 | 0 |
| CHI | 0 | 0 | 0 |
| COL | 0 | 0 | 0 |
| COR | 0 | 0 | 0 |
| CUB | 0 | 0 | 0 |
| DOR | 0 | 0 | 0 |
| ECU | 0 | 0 | 0 |
| ELS | 0 | 0 | 0 |
| GUT | 0 | 0 | 0 |
| HAI | 0 | 0 | 0 |
| HON | 0 | 0 | 0 |
| MEX | 0 | 0 | 0 |
| NIC | 0 | 0 | 0 |
| PAN | 0 | 0 | 0 |
| PAR | 0 | 0 | 0 |
| PER | 0 | 0 | 0 |
| URU | 0 | 0 | 0 |
| USA | 0 | 0 | 0 |
| VEN | 0 | 0 | 0 |
| Total | 0 | 0 | 0 |

CAR Incluye informes de todos sus Países Miembros

Cuadro No, 4
Casos compatibles de poliomieltis
por semana de inicio

Hasta la semana 13

| PAIS | TOTAL 2003 | Acumulado | |
|--------------|------------|-----------|----------|
| | | 2003 | 2004 |
| ARG | 0 | 0 | 0 |
| BOL | 2 | 2 | 0 |
| BRA | 0 | 0 | 0 |
| CAN | 0 | 0 | 0 |
| CAR | 0 | 0 | 0 |
| CHI | 0 | 0 | 0 |
| COL | 0 | 0 | 0 |
| COR | 0 | 0 | 0 |
| CUB | 0 | 0 | 0 |
| DOR | 0 | 0 | 0 |
| ECU | 0 | 0 | 0 |
| ELS | 0 | 0 | 0 |
| GUT | 1 | 0 | 0 |
| HAI | 0 | 0 | 0 |
| HON | 0 | 0 | 0 |
| MEX | 0 | 0 | 0 |
| NIC | 0 | 0 | 0 |
| PAN | 0 | 0 | 0 |
| PAR | 0 | 0 | 0 |
| PER | 0 | 0 | 0 |
| URU | 0 | 0 | 0 |
| USA | 0 | 0 | 0 |
| VEN | 0 | 0 | 0 |
| Total | 3 | 2 | 0 |

CAR Incluye informes de todos sus Países Miembros